US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Canada’s NanoVation Therapeutics, a privately-held platform company developing innovative technologies to overcome the barriers of nucleic acid delivery, has announced a multi-year partnership with Danish drugmaker Novo Nordisk. 18 September 2024
Gene therapy research in Japan has gained significant momentum due to the SAKIGAKE designation system and government-led initiatives like the “Project for Regenerative/Cellular Medicine and Gene Therapies” to accelerate research and development (R&D) to create new technologies for gene/cell therapy. 18 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
California, USA-based biotech BridgeBio Pharma saw its shares dip 4% to $29.60 yesterday on disappointing clinical results and the company’s decision to drop an early-stage candidate. 11 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
The Cell and Gene Therapy Catapult (CGT Catapult) has highlighted what it regards as the UK's potential to lead the global cell and gene therapy sector. 5 September 2024
Arsenal Biosciences, a programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, has announced the close of an oversubscribed $325 million Series C financing round. 4 September 2024
Chinese gene therapy specialist YolTech Therapeutics has entered into an exclusive licensing agreement with Salubris Pharmaceuticals (SHE: 002294). 3 September 2024
The UK’s National Health Service (NHS) got off to a good start with the introduction of cell and gene therapies but it must do more to get ready for the arrival of the advanced therapies of the future, according to a new report for the Association of the British Pharmaceutical Industry (ABPI). 19 August 2024
Japanese drugmaker Chugai Pharmaceutical has filed a regulatory application with the Ministry of Health, Labor and Welfare (MHLW) for gene therapy delandistrogene moxeparvovec, for the treatment of Duchenne muscular dystrophy (DMD). 15 August 2024
CRISPR genome-editing biopharma company Caribou Biosciences has announced the appointment of Tina Albertson as chief medical officer (CMO). 13 August 2024
Californian genetic medicines company 4D Molecular Therapeutics is free to continue with its Phase I/II INGLAXA study for the gene therapy 4D-310 in Fabry disease cardiomyopathy. 12 August 2024
Vertex Pharmaceuticalsrevealed a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access the CRISPR/Cas9 gene-edited therapy, Casgevy (exagamglogene autotemcel), from today. 8 August 2024
The Food and Drug Administration (FDA) has accepted and filed the efficacy supplement to the Biologics License Application (BLA) for Elevidys (delandistrogene moxeparvovec-rokl) submitted by US precision genetic medicines firm Sarepta Therapeutics. 16 February 2024
India has achieved a notable milestone in the field of cancer treatment with its indigenously developed CAR-T cell therapy, resulting in the first patient being declared cancer-free post treatment. 15 February 2024
The US Food and Drug Administration (FDA) has extended the Priority Review period for the Biologics License Application (BLA) for Kresladi (marnetegragene autotemcel; formerly RP-L201) for severe leukocyte adhesion deficiency-I (LAD-I). 14 February 2024
Leading Australian biotech CSL Limited has reported financial results for the six months to December 31, 2023, showing that revenue came in at A$8.05 billion ($12.3 billion, up 11% at constant currency (CC). 14 February 2024
Clinical stage gene therapy company MeiraGTx Holdings announced the achievement of the first milestone under the asset purchase agreement with Janssen Pharmaceuticals. 14 February 2024
Genetic disease company Vertex Pharmaceuticals has secured conditional marketing authorization for Casgevy (exagamglogene autotemcel) in Europe. 13 February 2024
Since the approval of the first CAR-T in 2017, T cell therapies have revolutionized the treatment of some blood cancers, and are one of the few cancer treatments to drive cures. 12 February 2024
French hearing loss specialist Sensorion has raised 50.5 million euros ($55 million), offering new shares at a price of 0.57 euro cents per share. 9 February 2024
Regenerative cell therapy specialist Neurona Therapeutics has raised $120 million in a financing round co-led by Viking Global Investors and Cormorant Asset Management. 9 February 2024
German biotech BioNTech and USA-based Autolus Therapeutics today announced a strategic collaboration aimed at advancing both companies’ autologous CAR-T programs towards commercialization, pending regulatory authorizations. 8 February 2024
US biotech major Gilead Sciences announced results of operations for the fourth quarter and full year 2023 after markets closed yesterday that were generally in line with Wall Street expectations. 7 February 2024
Augmenting its strategic push into cell therapies, British pharma major AstraZeneca has announced that it will construct a state-of-the-art facility in Maryland, USA. 7 February 2024
In late 2023, Vertex Pharmaceuticals and CRISPR Therapeutics’ made history by gaining the first FDA approval for a CRISPR-based drug, Casgevy (exagamglogene autotemcel) for the treatment of sickle cell disease with vaso-occlusive crisis. 6 February 2024
OneChain Immunotherapeutics (OCI), a Spanish biotech focused on the development of CAR-T therapies for the treatment of oncologic diseases, has named Stefanos Theoharis as the company's new chief executive. 1 February 2024
A new cell and gene therapy initiative from the USA's White House will launch with an initial focus on treatments for sickle cell disease (SCD). 1 February 2024
Adaptimmune Therapeutics saw its shares leap almost 10% by close of trading Wednesday and a further 5.2% to $1.01 in after-hours trading as it announced a regulator development for its cell therapy. 1 February 2024